Agboville RCT

• Arm 1 (comparator): Alb 400 mg plus IVM 200μg/kg body weight given at 0, 12 and 24 months
• Arm 2: ALB 400 mg (regardless of weight) given at 0, 6, 12, 18, and 24 months
• Arm 3: ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, and 24 months
• Arm 4*: ALB 400 mg plus IVM 200 μg/kg body weight plus DEC 6 μg/kg body weight given at time 0 only

*The fourth arm has been added to the trial because of encouaraging results with the triple drug regimin in Papua New Guinea. Subjects who will be reandomized into the triple drug arm in this open lable study will be screened for onchocerciasis by skin snips. Subjects with microfilaria positive skin snips will be excluded from the study.

Status:

Pilot testing completed and site identified -July/2013.  

Enrollment completed Q3/2015

Site Intitiation expected Q3/2015

Expected Trial completion- 2Q2018